{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T10:16:18Z","timestamp":1783332978711,"version":"3.54.6"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Labour Sciences Research from the Ministry of Health, Labour and Welfare","award":["23EA1035"],"award-info":[{"award-number":["23EA1035"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chemotherapy-induced peripheral neuropathy (CIPN) is a persistent and challenging adverse event of cancer treatment. This study aimed to describe current pharmacological and non-pharmacological approaches to CIPN and to examine their association with awareness of the Japanese clinical guideline (CIPN-GL2023).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An online survey was distributed to healthcare professionals involved in CIPN management, including physicians, pharmacists, and nurses. Participants reported whether they recommended pharmacological and non-pharmacological interventions for prevention and treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 450 valid responses, 31% recommended pharmacological prevention, whereas 89% and 97% recommended pharmacological treatment for numbness and pain, respectively. Non-pharmacological strategies were recommended by 57% for prevention and 55% for treatment. Participants who were aware of the guideline were less likely to recommend pharmacological prevention and more likely to implement non-pharmacological prevention and treatment. Duloxetine, pregabalin, and mirogabalin (gabapentinoids) were commonly recommended across prevention and treatment. Guideline awareness was significantly associated with the recommendation of duloxetine for pain (65% vs. 44%, P\u00a0&amp;lt;\u00a0.01). Exercise and cryotherapy were frequently recommended for prevention, and exercise was the predominant non-pharmacological treatment. Exercise for prevention was more common as a first-line approach among guideline-aware respondents (56% vs. 35%, P\u00a0=\u00a0.02). Pharmacists demonstrated significantly higher guideline awareness, while nurses more frequently adopted non-pharmacological therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Awareness of CIPN-GL2023 was associated with increased evidence-based practice, particularly through the use of duloxetine for pain and exercise for prevention. Multidisciplinary engagement and targeted efforts to reduce non-recommended practices remain important for improving CIPN management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyag045","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T12:23:01Z","timestamp":1772454181000},"page":"865-872","source":"Crossref","is-referenced-by-count":0,"title":["Current pharmacological and non-pharmacological approaches to chemotherapy-induced peripheral neuropathy and association with awareness of clinical guidelines"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7961-697X","authenticated-orcid":false,"given":"Sena","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Division of Health Sciences, The University of Osaka Graduate School of Medicine , 1-7 Yamadaoka, Suita, Osaka 565-0871 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9747-9828","authenticated-orcid":false,"given":"Harue","family":"Arao","sequence":"additional","affiliation":[{"name":"Division of Health Sciences, The University of Osaka Graduate School of Medicine , 1-7 Yamadaoka, Suita, Osaka 565-0871 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Nawata","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmaceutics, School of Pharmacy , Showa Medical University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555 ,","place":["Japan"]},{"name":"Department of Pharmacy, Showa Medical University Northern Yokohama Hospital , 35-1 Chigasaki-chuo, Tsuzuki-ku, Yokohama, Kanagawa 224-8503 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6048-2502","authenticated-orcid":false,"given":"Toshihisa","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Cancer Center Japan Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]},{"name":"Office of Infection Control and Prevention, National Cancer Center Japan Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Hanai","sequence":"additional","affiliation":[{"name":"Faculty of Informatics, Chiba University , 1-33 Yayoi-cho, Inage-ku, Chiba City, Chiba 263-8522 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kogawa","sequence":"additional","affiliation":[{"name":"Department of Advanced Medical Development, Cancer Institute Hospital of Japanese Foundation for Cancer Research , 3-8-31, Ariake, Koto-ku, Tokyo 135-8550 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6583-7352","authenticated-orcid":false,"given":"Yoichiro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine , 7-45-1 Nanakuma, Jonan-Ku, Fukuoka City, Fukuoka 814-0180 ,","place":["Japan"]},{"name":"Department of Medical Informatics and Digital Medicine, Fukuoka University Hospital , 7-45-1 Nanakuma, Jonan-Ku, Fukuoka City, Fukuoka 814-0180 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"2026070605420990400_ref1","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"2026070605420990400_ref2","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.annonc.2020.07.003","article-title":"Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO\u2013EONS\u2013EANO clinical practice guidelines for diagnosis, prevention, treatment and follow-up","volume":"31","author":"Jordan","year":"2020","journal-title":"Ann Oncol"},{"key":"2026070605420990400_ref3","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"32","author":"Hershman","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026070605420990400_ref4","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026070605420990400_ref5","volume-title":"Clinical guidelines of Management for Chemotherapy-Induced Peripheral Neuropathy","author":"Japanese Association of Supportive Care in Cancer","year":"2023"},{"key":"2026070605420990400_ref6","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1093\/jjco\/hyaa056","article-title":"Effects of the publication of clinical guidelines for the Management of Chemotherapy-Induced peripheral neuropathy on the administration preferences of oncology specialists: Japanese Association of Supportive Care in cancer","volume":"50","author":"Hirayama","year":"2020","journal-title":"Jpn J Clin Oncol"},{"key":"2026070605420990400_ref7","doi-asserted-by":"publisher","first-page":"151685","DOI":"10.1016\/j.soncn.2024.151685","article-title":"Exploring chemotherapy-induced peripheral neuropathy management practice patterns among oncology clinicians","volume":"40","author":"Kanzawa-Lee","year":"2024","journal-title":"Semin Oncol Nurs"},{"key":"2026070605420990400_ref8","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s00520-025-09387-9","article-title":"Practice patterns in the diagnosis and management of chemotherapy-induced peripheral neuropathy in adolescents and young adults with cancer: a survey of oncologists","volume":"33","author":"Belsky","year":"2025","journal-title":"Support Care Cancer"},{"key":"2026070605420990400_ref9","doi-asserted-by":"publisher","first-page":"100581","DOI":"10.1016\/j.apjon.2024.100581","article-title":"Knowledge levels of oncology nurses regarding evidence-based practices in the assessment and management of chemotherapy-induced peripheral neuropathy","volume":"11","author":"\u00c7elik","year":"2024","journal-title":"Asia Pac J Oncol Nurs"},{"key":"2026070605420990400_ref10","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1188\/14.ONF.669-679","article-title":"Nursing knowledge, practice patterns, and learning preferences regarding chemotherapy-induced peripheral neuropathy","volume":"41","author":"Smith","year":"2014","journal-title":"Oncol Nurs Forum"},{"key":"2026070605420990400_ref11","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1007\/s00520-025-10166-9","article-title":"Evidence-based nursing care practice for chemotherapy-induced symptomatic adverse reactions in Japanese hospitals: a cross-sectional study focusing on chemotherapy-induced skin toxicities, peripheral neuropathy, and fatigue","volume":"33","author":"Shimizu","year":"2025","journal-title":"Support Care Cancer"},{"key":"2026070605420990400_ref12","doi-asserted-by":"publisher","first-page":"e000053","DOI":"10.1136\/esmoopen-2016-000053","article-title":"Survey of the management of chemotherapy-induced peripheral neuropathy in Japan: Japanese Society of Medical Oncology","volume":"1","author":"Hirayama","year":"2016","journal-title":"ESMO Open"},{"key":"2026070605420990400_ref13","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA"},{"key":"2026070605420990400_ref14","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/s10147-015-0810-y","article-title":"Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial","volume":"20","author":"Hirayama","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"2026070605420990400_ref15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40261-019-00882-6","article-title":"Comparison of the efficacy and safety of pregabalin and duloxetine in taxane-induced sensory neuropathy: a randomized controlled trial","volume":"40","author":"Salehifar","year":"2020","journal-title":"Clin Drug Investig"},{"key":"2026070605420990400_ref16","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s00520-015-2807-5","article-title":"Can pregabalin prevent paclitaxel-associated neuropathy?\u2014an ACCRU pilot trial","volume":"24","author":"Shinde","year":"2016","journal-title":"Support Care Cancer"},{"key":"2026070605420990400_ref17","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1634\/theoncologist.2017-0235","article-title":"Pregabalin for the prevention of oxaliplatin-induced painful neuropathy: a randomized, double-blind trial","volume":"22","author":"Andrade","year":"2017","journal-title":"Oncologist"},{"key":"2026070605420990400_ref18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1136\/spcare-2022-003815","article-title":"Duloxetine for prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN): systematic review and meta-analysis","volume":"13","author":"Chow","year":"2023","journal-title":"BMJ Support Palliat Care"},{"key":"2026070605420990400_ref19","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/s41416-021-01471-1","article-title":"Preventive effect of sensorimotor exercise and resistance training on chemotherapy-induced peripheral neuropathy: a randomised-controlled trial","volume":"125","author":"M\u00fcller","year":"2021","journal-title":"Br J Cancer"},{"key":"2026070605420990400_ref20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1177\/1545968319899918","article-title":"An exploratory randomized trial of physical therapy for the treatment of chemotherapy-induced peripheral neuropathy","volume":"34","author":"Andersen Hammond","year":"2020","journal-title":"Neurorehabil Neural Repair"},{"key":"2026070605420990400_ref21","doi-asserted-by":"publisher","first-page":"1346099","DOI":"10.3389\/fneur.2024.1346099","article-title":"Exercise intervention for the management of chemotherapy-induced peripheral neuropathy: a systematic review and network meta-analysis","volume":"15","author":"Nakagawa","year":"2024","journal-title":"Front Neurol"},{"key":"2026070605420990400_ref22","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1200\/JCO.22.00687","article-title":"Exercise, diet, and weight management during cancer treatment: ASCO guideline [ASCO guideline]","volume":"40","author":"Ligibel","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026070605420990400_ref23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12966-021-01116-9","article-title":"Factors influencing physical activity participation among people living with or beyond cancer: a systematic scoping review","volume":"18","author":"Elshahat","year":"2021","journal-title":"Int J Behav Nutr Phys Act"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/7\/865\/68432997\/hyag045.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/7\/865\/68432997\/hyag045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:42:12Z","timestamp":1783330932000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/7\/865\/8698158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":23,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,5,29]]},"published-print":{"date-parts":[[2026,7,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag045","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,5,29]]}}}